-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Oruka Therapeutics, Maintains $45 Price Target

Benzinga·03/13/2026 12:31:34
Listen to the news
Wedbush analyst Martin Fan reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Outperform and maintains $45 price target.